CEO SUMMARY: During the past year, Luminex Corporation moved swiftly to push its LabMAP™ multiplex testing technology into the bioassay marketplace. It found high interest among companies in the pharmaceutical, diagnostics, and bioresearch industries. Luminex executives say that a number of companies are working to have FDA-approved diagnostic test kits available for laboratories by year’s …
Luminex Raises $83 Mil In Public Stock Offering Read More »
To access this post, you must purchase The Dark Report.